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The  mood  stabilizer  valproic  acid  (VPA)  decreases  neural  progenitor  proliferation  and  promotes  neuroge-
nesis in  the  adult  hippocampus.  However,  the  effects  of  VPA  on  progenitor  cells  in  the  adult  subventricular
zone  (SVZ)  are  not  as  well  characterized.  Here  we  report  VPA  blocks  neurosphere  formation  and  inhibits
DNA synthesis  in  cultured  NSCs  from  the  SVZ  of adult  mice.  Inhibition  of  DNA  synthesis  is associated  with
the  up-regulation  of the  differentiation  transcription  factors  Egr1  and  Neurod1  and  down-regulation  of
transcription  factors  associated  with  “stemness”.  Co-treatment  of VPA  with  the  mood  stabilizer  lithium
antagonizes  the  anti-proliferative  effects  of  VPA  on  adult  NSCs  and  abolishes  VPA  activation  of  Egr1.
Co-treatment  of  VPA  with  the  MEK1/2  inhibitor  PD980589  similarly  abolishes  Egr1  activation  consistent
with  VPA  activation  and  lithium  antagonism  of  MEK-ERK  signaling  in  adult  NSCs.  However,  Western
blot  reveals  VPA  significantly  suppresses  ERK2  phosphorylation  in  adult  NSCs  grown  in proliferating  cul-
ture conditions  and that lithium  co-treatment  does  not  attenuate  this  effect.  Combined  the  data  indicate
VPA inhibition  of  adult  NSC  proliferation  and  activation  of  Egr1  by  VPA,  along  with  the  antagonism  of
these  effects  by  lithium,  are  the  effects  of  cumulative  changes  in  multiple  signaling  pathways  and  are  not
attributable  to  a  common  kinase  target.
Published by Elsevier Ireland Ltd.
Valproic acid (VPA, valproate) is a commonly prescribed anti-
convulsant and mood stabilizer used in the treatment of epilepsy
and bipolar disorder. VPA treatment reduces neuronal damage and
aberrant neurogenesis associated with epileptic activity in adult
rodents [3,15].  Conversely, VPA treatment promotes neurogene-
sis in non-pathological adult rodent models [12,14] indicating the
drug has complex, context-dependent effects. VPA affects various
cell signaling systems that likely contribute to the drug’s properties.
These include mitogen activated protein kinase (MAPK) signaling
[12,16], glycogen synthase kinase-3 (GSK-3) activity [5] and inos-
itol and phospholipid signaling [4,22].  Furthermore, at high doses
VPA inhibits histone deacetylase (HDAC) activity [11] and HDAC-
mediated responses are proposed to contribute to the differential
neurogenic effects of VPA in the normal and epileptic adult rodent
brain [14,15,23].
Abbreviations: MEK, MAP kinase or ERK kinase; NaB, sodium butyrate; NSC,
neural stem cell; VPA, valproic acid.
∗ Corresponding author at: Center for Neuroscience and Regenerative Medicine,
Physiology and Genetics, Uniformed Services University of the Health Sciences, 4301
Jones Bridge Road, Bethesda, MD  20814, United States. Tel.: +1 301 295 3206;
fax:  +1 301 295 1786.
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VPA-stimulated neurogenesis has been linked to activation of
ERK pathway signaling in cultured embryonic forebrain progenitors
and in the adult hippocampus and frontal cortex [9,12,16]. In this
study, we have examined the effects of VPA on proliferating neural
stem cells (NSCs) cultured from the SVZ of adult mice. We  used
neurosphere formation in culture as a model system to determine
the molecular targets of VPA in proliferating adult NSCs.
8–10 week old male and female (equal numbers) C57BL/6J
mice were purchased from The Jackson Laboratory and housed in
the Uniformed Services University’s (USU) Center for Laboratory
Animal Medicine. Animals were handled in accordance with pro-
cedures approved by the USU Institutional Animal Care and Use
Committee (IACUC) and DoD regulations as published in DoD  Direc-
tive 3216.1.
Adult neural stem cells (NSCs) were harvested and cultured from
the subventricular zone (SVZ) of adult C57BL/6J mice as described in
[25]. Cells were passaged a minimum 5 times prior to experimental
analysis to ensure a high enrichment of multipotent stem cells.
Valproic acid sodium salt (Sigma) or sodium butyrate sodium
salt (Sigma) was added to culture media to a final 1 mM con-
centration at 3-h post-passage. For co-treatment experiments,
lithium/selective kinase inhibitor was added 30 min  prior to the
addition of valproic acid/sodium butyrate. The final concentra-
tions of co-treated drugs in media were: (1) 3 mM lithium chloride
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(Sigma); (2) 30 M MEK1/2 inhibitor PD980589 (Cell Signaling
Technology); (3) 10 M GSK-3 inhibitor SB 216763 (Sigma); and
(4) 10 M CREB–CREB binding protein (CBP) interaction inhibitor
217505 (EMD Biosciences). An equal volume of DMSO/water only
was added to the media of vehicle control cultures.
All procedures were performed according to the manufac-
turer’s instructions (Invitrogen). For combined cell cycle analysis,
adult NSCs cultures were pulsed overnight (16 h) with 10 M 5-
ethynyl-2′-deoxyuridine (EdU) in cell culture media at 37 ◦C, 5% CO2
and co-labeled with CellCycle 488-red (7-AAD) and LIVE/DEAD®
Fixable Violet stains. For combined drug treatments (VPA plus
LiCl/PD980589/SB 216763/217505) adult NSC cultures were EdU
pulsed for 4 h in cell culture media at 37 ◦C, 5% CO2. Flow cytometry
and data collection were performed as described in [25].
Adult NSCs were incubated with a 0.2% solution of trypan-blue
dye and small cell clusters/neurospheres excluding dye counted as
described in [25].
Real-time quantitative reverse transcription PCR (qRT-PCR)
was performed as described in [8].  Optimum primers were
designed using NCBI’s Primer BLAST. Primer sequence pairs
used are: Actb GGCTGTATTCCCCTCCATCG and CCAGTTG-
GTAACAATGCCATGT; Egr1 GGGAGAGGCAGGAAAGACATTT
and TCTGAGATCTTCCATCTGACCTAAGA; Gapdh CCCCVGCAAG-
GACACTGAGCAAGAG and GCCCCTCCTGTTATTATGGGGGTC;
Hes1 TGGCGGCTTCCAAGTGGTGC and GATGACCGGGCCGCT-
GTGAG; Hprt1 ACGGGGGACATAAAAGTTATTGGTGG and
ACCATTTTGGGGCTGTACTGCTTAAC; Hsp90 GCTTGCCGT-
GCGAGTCGGAC and CCACCTCCTCCTCTCCATGGTGC; c-Myc
ACCCGCTCAACGACAGCAGC and CCGTGGGGAGGACTCGGAGG;
Neurod1 CCGCCACACGCCTACA and CAAACTCGGCGGATGG;
Sox2 GAAAGAAAGGAGAGAAGTTTGGAG and ATCTGGCGGA-
GAATAGTTGGG. Ct values were normalized to Ct values for Gapdh,
Actb, Hprt1 and/or Hsp90. All values represent a minimum of 3
biological replicates.
Nuclear and cytoplasmic proteins were isolated from adult NSCs
using NE-PER® reagents (Thermo Scientific) according to the man-
ufacturer’s instructions (Thermo Scientific) and Western blots of
protein extracts (10–20 g protein/lane) performed as described
in [25]. Primary antisera/dilutions used were: 1:1000 rabbit mon-
oclonal anti-CREB; 1:1000 rabbit monoclonal anti-phospho-CREB;
1:1000 rabbit monoclonal anti-GSK-3; 1:1000 rabbit polyclonal
anti-phospho-GSK-3/; 1:1000 PathScan® Multiplex Western
Cocktail I of rabbit polyclonals anti-phospho-p90-RSK, anti-
phospho-Akt, anti-phospho-p44/42 MAPK, anti-phopho-S6 and
anti-EIF4e (all Cell Signaling Technology); 1000 mouse monoclonal
anti-Gapdh (Millipore): or 1000 mouse monoclonal anti-Laminin
A/C (BD Biosciences).
We first examined the effects of chronic VPA treatment on neu-
rosphere formation by adult neural stem cells (NSCs). NSCs from
the adult SVZ were grown in proliferating culture conditions with
1 mM VPA for 2–7 days (1 mM VPA has been shown to inhibit the
proliferation of hippocampal progenitor cells and promote neuro-
genesis in culture, see [14,23]). VPA-treated adult NSCs produce
fewer neurospheres of comparable size or density when compared
to vehicle-treated controls (Fig. 1a). Reduced neurosphere forma-
tion is noticeable at 24 h treatment and persists for the full 7 days
treatment regimen. Quantification at 7-days VPA treatment reveals
an 8.1 ± 3.0 fold-decrease in the number of neurospheres (diame-
ter ≥ 50 m)  in VPA treated cultures (n = 4). The number of small
cell clusters (≥4 cells, diameter < 50 m)  increases 5.0 ± 2.1 fold in
VPA treated cultures (n = 4) consistent with the continued survival
of non-neurosphere forming cells. Quantification of the toxic effects
of 1 mM VPA on adult NSCs using LIVE/DEAD staining and flow
cytometry reveals VPA treatment results in a 9.6 ± 4.2% reduction
in cell viability compared to vehicle controls after 48 h treatment, a
difference in cell viability that did not reach statistical significance
(P = 0.09, unpaired t-test, n = 3). Combined these results indicate
chronic VPA treatment results in a mildly toxic inhibition of adult
NSC proliferation in culture.
We next quantified VPA’s effects on DNA synthesis (S phase) by
measuring incorporation rates of the thymidine analog nucleoside
EdU (5-ethynyl-2′-deoxyuridine). Adult NSCs were treated with
1 mM VPA or vehicle for 48 h in proliferating culture conditions and
pulsed with 10 M EdU for the final 16 h of treatment. Flow cytom-
etry reveals EdU incorporation is 3-fold lower in live cell gated
adult mouse NSCs treated with VPA compared to vehicle controls
(18.3 ± 2.1% versus vehicle 54.5 ± 7.5% vehicle, P < 0.001, see Fig. 1b
and c). To determine whether VPA suppression of S phase DNA syn-
thesis is associated with cell cycle arrest, we estimated cell cycle
stage by flow cytometry using the Dean–Jett–Fox model (Flowjo
software). This revealed a small, statistically insignificant increase
in the percentage of cells in G1 phase (51.1 ± 1.4% versus 47.9 ± 1.3%
vehicle, P > 0.05) and corresponding decrease in the percentage of
cells in G2/M phase (19.0 ± 1.3% versus 24.8 ± 1.7% vehicle, P > 0.05)
of the cell cycle (Fig. 1c). Accordingly, we  conclude chronic VPA
treatment inhibits adult NSC proliferation in culture by S phase
inhibition unassociated with significant arrest in either G1 or G2/M
phase of the cell cycle.
Lithium, like VPA, is a commonly prescribed mood stabilizer
[10] and the two  drugs have overlapping mechanisms of activity
[5,9,17,22]. We  examined the effects of lithium co-treatment on
the anti-proliferative effects of VPA to determine common molec-
ular targets. Adult NSCs grown in proliferating conditions were
treated for 48 h with VPA, VPA plus lithium chloride (3 mM  LiCl)
or vehicle, pulsed with EdU for the final 4 h of treatment and the
cells analyzed by flow cytometry. Co-treatment of VPA with lithium
results in significantly higher adult NSC proliferation rates than
those treated with VPA alone (Fig. 1d). The addition of lithium to
VPA increases EdU incorporation rates in adult NSCs 1.8-fold (VPA
9.59 ± 1.07 versus VPA and lithium 17.23 ± 1.71 EdU+ve, P < 0.01,
n = 4), indicating an antagonistic response to the addition of lithium.
To assess the importance of HDAC inhibitor-mediated effects
in the antagonism of VPA proliferative responses by lithium, we
examined the effects of lithium co-treatment with sodium butyrate
(NaB), a molecule with similar class I/II HDAC inhibitor properties to
VPA. Using the same culture assay, 1 mM  NaB inhibits neurosphere
formation by NSCs from the adult mouse SVZ [25]. In contrast to
VPA/lithium co-treatment, NaB/lithium co-treatment does not sig-
nificantly decrease the anti-proliferative effects of NaB (P = 0.63,
n = 4), see Fig. 2. Combined the data suggests lithium antagonizes
VPA sensitive cell signaling mechanisms other than HDAC inhibi-
tion to reduce the anti-proliferative effects of VPA on adult NSCs.
We measured mRNA levels in adult NSCs treated with VPA or
vehicle to identify changes in adult NSC gene expression associated
with treatment effects. Real-time PCR reveals chronic VPA treat-
ment up-regulates the immediate early gene transcription factor
Egr1 (Krox24, Zif268) and more robustly the pro-neural transcrip-
tion factor Neurod1 in adult NSCs (Fig. 2a). In contrast, Hes1, c-Myc
and Sox2 transcription factors associated with the maintenance
of a stem/progenitor cell state are down-regulated in adult NSCs
(Fig. 2a).
We  next asked if these VPA-modulated changes in transcrip-
tion correlated with the antagonism of VPA effects by lithium
co-treatment. Real-time PCR revealed co-treatment of VPA with
lithium reverses VPA-mediated increases in Egr1 transcription
(Fig. 2b). In contrast, Neurod1 up-regulation and Hes1, c-Myc and
Sox2 down-regulation by VPA were unaffected by lithium co-
treatment (not shown). This suggests a specific correlation between
Egr1 activation and the antagonism of VPA inhibition of prolifera-
tion by lithium.
Egr1 is induced by growth factors through ERK/CREB (cAMP-
response element-binding protein) activation (for review see [2])
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Fig. 1. Chronic VPA treatment inhibits adult mouse NSC proliferation and neuro-
sphere formation in culture. (a) Light micrographs of adult NSC cultures following
chronic 7-day treatment with 1 mM VPA or vehicle. Adult NSCs were grown
in  proliferating culture conditions and treated with VPA or water vehicle. Scale
bar  = 100 m.  (b) Fluorescence micrographs of 1 mM VPA and vehicle treated adult
NSCs pulse-labeled with EdU for flow cytometry. Scale bar = 50 m.  (c) Analysis of
EdU  incorporation and DNA content by flow cytometry reveals chronic 1 mM VPA
treatment significantly inhibits DNA synthesis (**P < 0.01) by adult NSCs in culture
but is not associated with significant arrest in G1 or G2/M phase (P-values > 0.05)
of  the cell cycle (1-way ANOVA with post hoc Newman-Keuls multiple comparison
tests, n = 3). Adult NSCs were treated with 1 mM VPA or vehicle for 48 h in pro-
liferating culture conditions, pulsed with EdU for the final 16 h of treatment and
processed for flow cytometry. (d) Co-treatment with lithium significantly reduces
the  anti-proliferative effects of VPA but not of the HDAC inhibitor sodium butyrate
(NaB). Adult NSCs were treated with 1 mM VPA, 1 mM VPA plus 3 mM lithium chlo-
ride (LiCl), 1 mM NaB or 1 mM NaB plus 3 mM LiCl for 48 h, pulsed with EdU for
the  final 4 h of treatment and processed for flow cytometry. EdU incorporation is
significantly increased 1.8 fold by lithium co-treatment with VPA compared to VPA
alone (**P  < 0.01, t-test, n = 4). In contrast, lithium co-treatment with NaB results in
a  smaller 1.3 fold increase in EdU incorporation compared to NaB alone that is not
significantly different (P = 0.63, t-test, n = 4).
Fig. 2. Chronic VPA treatment activates Egr1 gene transcription in proliferating
adult NSCs via a lithium and MEK1/2 sensitive mechanism. Adult NSCs were
treated with 1 mM VPA or vehicle for 48 h in proliferating culture conditions and
gene expression measured by qRT-PCR. For co-treatments, lithium/selective kinase
inhibitor was added 30 min prior to the addition of VPA. Cells were harvested
for  qRT-PCR after 48 h treatment and all qPCR values calculated from ≥3 biologi-
cal replicates. (a) Chronic VPA treatment up-regulates differentiation transcription
factors Egr1 and more robustly Neurod1 in adult NSCs grown in proliferating
culture conditions (**P < 0.01, t-test, n = 5). In contrast, Hes1, c-Myc and Sox2 tran-
scription factors associated with the maintenance of a stem/progenitor cell state
are down-regulated. (b) Co-treatment with lithium or with the MEK1/2 inhibitor
PD98095 blocks VPA activation of Egr1 transcription in adult NSCs grown in pro-
liferating culture conditions. Adult NSCs were treated with 3 mM LiCl, 30 M of
the MEK1/2 inhibitor PD98095, 10 M CREB-CBP interaction inhibitor 217505,
10  M of the GSK-3 inhibitor SB 216763 or vehicle 30 min  prior to the addition
of 1 mM VPA. VPA-mediated increase in Egr1 transcript levels is significantly sup-
pressed by co-treatment with LiCl or PD98095 (*P < 0.05 1-way ANOVA with post
hoc Newman–Keuls multiple comparison tests, n ≥ 3).
and we  speculated antagonism of VPA effects on ERK/CREB signal-
ing by lithium could account for changes in Egr1 transcription. To
test this hypothesis we  measured mRNA levels of Egr1 in adult NSCs
treated with VPA plus selective kinase inhibitors. We co-treated
cells with PD98059 (30 M),  a highly selective inhibitor of MEK1/2
activation and the MEK-ERK cascade [7],  with 217505 (10 M)  a
small molecule shown to disrupt the interaction between CREB
and CREB binding protein (CBP) [1] and, in view of the known
inhibitory effects of lithium on GSK-3 activity [24], with the GSK-
3 inhibitor SB 216763 (10 M).  This analysis revealed inhibition
of MEK1/2 but not CREB-CBP interaction or GSK-3 activity antago-
nized VPA-mediated increases in Egr1 transcription (Fig. 2b). This
indicates VPA modulates MEK-ERK signaling independent of the
downstream transcriptional regulator CREB or GSK-3 to activate
Egr1.
Down-regulation of Egr1 with MEK-ERK inhibition or lithium
raises the possibility lithium co-treatment inhibits MEK-ERK sig-
naling to antagonize the effects of VPA. Indeed, VPA has been
shown to activate ERK signaling in embryonic cortical progenitor
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Fig. 3. Chronic VPA treatment inhibits ERK2 activation in adult NSCs grown in proliferating culture conditions. (a) Chronic (48 h) treatment with 1 mM VPA  substantially
reduces nuclear ERK2 phosphorylation levels in proliferating adult NSCs. Chronic co-treatment of adult NSCs with 1 mM VPA plus 3 mM LiCl results in only minor changes in
phospho-kinase levels. Laminin a/c and Gapdh immunosignals are shown to demonstrate nuclear/cytosol enrichment. (b) Densitometric quantification of Western blot signal
intensities normalized to loading controls confirms chronic VPA treatment significantly reduces nuclear ERK2 phosphorylation levels in proliferating adult NSCs (**P < 0.01
1-way ANOVA with Bonferroni post-tests, n = 3). Differences in the levels of all other phospho-kinases were not statistically significant from vehicle controls and no statistical
difference was  detected between phospho-kinase levels in VPA versus VPA plus lithium treated samples (1-way ANOVA with Bonferroni post-tests, n = 3–5). Phospho-ERK1/2,
phospho-AKT and phospho-S6 levels were normalized to EIF4E signals (Kinase Path Scan® antibody cocktail, Cell Sig. Tech.). Phospho-CREB and phosho-GSK-3 levels were
normalized to total anti-CREB or total anti-GSK-3 signal intensities, respectively (all antibodies Cell Sig. Tech). Protein signal intensities were calculated from 3–5 biological
replicates.
cells [12,16].  We  analyzed the phosphorylation levels of a selec-
tion of kinases in adult NSCs to identify VPA sensitive cell signaling
mechanisms antagonized by lithium. Western blot reveals chronic
VPA treatment significantly reduces rather than enhance ERK2
phosphorylation in adult NSCs grown in proliferating culture con-
ditions (P < 0.01) (Fig. 3). Furthermore, lithium co-treatment does
not attenuate the inhibitory effect of VPA on ERK2 phosphoryla-
tion (Fig. 3); each kinase shows only small, non-significant changes
to their phosphorylation in response to lithium when compared
to VPA alone (P > 0.05, n ≥ 3). Taken together the Western blot data
suggest the reduction of VPA inhibition of adult NSC proliferation by
lithium co-treatment is the effect of cumulative changes in multiple
signaling pathways rather than via a common kinase target.
In this study we demonstrate the mood stabilizer valproic acid
(VPA) modulates gene expression and kinase activity in adult NSCs
to inhibit proliferation and neurosphere formation in culture. VPA
inhibition of adult NSC proliferation was associated with the tran-
scriptional activation of the immediate early gene transcription
factor Egr1, a gene linked to de novo neurogenesis functions in
adult mice [20,21]. Egr1 is activated by nerve growth factor (NGF)
stimulation of the ERK pathway in PC12 cells and is required
for NGF-induced neurite outgrowth [13,18] and VPA has been
shown to activate ERK signaling in the developing embryonic cortex
[16]. However, chronic VPA treatment suppressed ERK2 phospho-
rylation in adult NSCs. Furthermore, lithium antagonism of the
anti-proliferative effects and activation of Egr1 by VPA was not
associated with lithium induced changes in ERK2 phosphorylation.
Combined these data support the idea that VPA suppresses prolif-
eration and activates Egr1 differentiation signals in cultured adult
NSCs via the modulation of multiple signaling pathways.
There is good evidence to suggest reduced ERK2 phospho-
rylation and suppressed MAPK-ERK signaling accounts for the
inhibition of adult NSC proliferation by VPA. FGF-2 is a potent
inducer of adult NSC proliferation, inducing sustained ERK1/2 phos-
phorylation in adult NSCs, and genetic studies confirm MAPK-ERK
signaling is required for the maintenance of adult NSC prolifera-
tion and suppression of differentiation by FGF-2 [19]. Interestingly,
genetic attenuation of MAPK-ERK signaling activates Neurod1
expression and promotes differentiation in FGF-2 treated adult
NSCs [19]. However, VPA activation of Neurod1 in adult hippocam-
pal progenitors, like Egr1 activation in our adult SVZ NSCs, is
independent of MAPK-ERK pathway activation [14]. In the case of
Neurod1, transcriptional activation of pro-neural basic helix-loop-
helix transcription factors upstream of Neurod1 [23] could account
for Neurod1 up-regulation. Chromatin immunoprecipitation data
from our laboratory (unpublished) indicates VPA indirectly acti-
vates Egr1. It is possible Egr1 activation involves multiple molecular
mechanisms, as appears to be the case for VPA induction of Bcl-2
expression in human neuroblastoma cells in which VPA triggers
a signaling cascade of ERK and/or PI3K (phosphatidylinositol 3-
kinase) activation of RSK (p90 ribosomal S6 kinase) to up-regulate
Bcl-2 transcription, and yet chemical inhibition of ERK/PI3K or RSK
shRNA knockdown attenuates but does not abolish Bcl-2 induction
by VPA [6].  In summary, our data indicate the effects of VPA alone or
in co-treatment with lithium on cultured adult NSCs are the result
of cumulative changes in multiple signaling pathways and are not
attributable to a common kinase target.
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